Previous studies have revealed that some patients with RA possess cross-reactive anti-PAD3/PAD4 antibodies, which activate enzymes by increasing calcium affinity and promote disease progression (32, –34). This evidence concerns the gene PADI4 and rheumatoid arthritis.